Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil
The transcription factor NRF2 is constitutively active in glioblastoma, a highly aggressive brain tumor subtype with poor prognosis. Temozolomide (TMZ) is the primary chemotherapeutic agent for this type of tumor treatment, but resistance to this drug is often observed. This review highlights the re...
Bewaard in:
| Hoofdauteurs: | , , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
MDPI AG
2023-04-01
|
| Reeks: | Biomedicines |
| Onderwerpen: | |
| Online toegang: | https://www.mdpi.com/2227-9059/11/4/1081 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|